Does the FDA support personalized HRT dosing

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, the FDA supports individualized dosing of commercially available hormone therapy, but it does not endorse compounded hormone products as a safer or more effective form of individualization. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

What the FDA Supports

According to FDA.gov, women may have their hormone therapy dose adjusted to match their symptoms, goals, and side effects. This is what individualized dosing means in practice: a qualified prescriber chooses the dose and formulation appropriate for the individual patient. All commercially available HRT products come in multiple strengths, allowing for this stepwise dose adjustment.

According to FDA-approved prescribing information for commercially available HRT products, this type of individualization should be carried out using commercially available medications, which are tested for purity, potency, and consistency, making dosing more predictable.

What the FDA Does Not Support

According to FDA.gov, the FDA does not support the claim that compounded hormone products are safer, more natural, or more precisely matched to individual needs. Commercially available products undergo pre-market review for consistency, potency, and long-term safety, while compounded hormone products do not. Because of this, according to FDA Drug Safety Communication, dosing with compounded hormones may be unpredictable, even when labeled as individualized.

According to FDA.gov, hormone testing methods marketed for fine-tuned dosing — such as saliva testing — are not reliable for guiding hormone therapy decisions. Hormone levels fluctuate throughout the day, and a qualified prescriber's clinical judgment based on symptoms remains the more appropriate guide.

What Individualized Dosing Means in Practice

• Start low and adjust gradually. A qualified prescriber may increase or decrease the dose based on how the patient responds to treatment.
• Use consistent, tested products. Commercially available products help keep each dose stable and predictable.
• Match the route to the patient's health profile. For example, according to NAMS, transdermal estrogen may be considered when venous clot risk is a concern.
• Ongoing clinical check-ins. Dose adjustments may continue as symptoms change over time.

According to FDA.gov, the FDA supports thoughtful, individualized dosing of hormone therapy using commercially available products. What the FDA does not support is unregulated compounding marketed as a form of individualization. Individualized dosing using commercially available products, small dose adjustments, and close attention to symptoms by a qualified prescriber is the approach consistent with FDA guidance.